Trial in progress: QUINTESSENTIAL-2—a phase 3 Study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

The QUINTESSENTIAL-2 trial is a phase 3 study evaluating arlocabtagene autoleucel (arlo-cel), a GPRC5D-directed CAR T-cell therapy, against standard care in adults with relapsed/refractory multiple myeloma refractory to lenalidomide. Enrolling 440 patients, the study compares efficacy—specifically progression-free survival and MRD negativity—to standard regimens like DPd or Kd. This global trial assesses arlo-cel's potential to improve clinical outcomes.